News | May 27, 2021
Sun Pharma Q4 FY21 net profit up 124%
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
India sales grew 23.5% YoY with consolidation of Wockhardt products
Subscribe To Our Newsletter & Stay Updated
